BCLSI
SAGE

Bain Capital Life Sciences Investors’s Sage Therapeutics SAGE Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-499,100
Closed -$30.5M – 28
2020
Q3 		$30.5M Hold
499,100
– – 2.84% 9
2020
Q2 		$20.8M Buy
+499,100
New +$18.1M 2.17% 11

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bain Capital Life Sciences Investors's SAGE Position: Q4 2020 in Review

Bain Capital Life Sciences Investors sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 499,100 shares — an estimated $30.5M sold.

Bain Capital Life Sciences Investors first reported a position in SAGE in Q2 2020 and held it in 2 quarters. The position peaked at $30.5M in Q3 2020. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

  • Bain Capital Life Sciences Investors reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 499,100 Sage Therapeutics shares in Q4 2020, an estimated $30.5M.
  • Bain Capital Life Sciences Investors first reported a position in Sage Therapeutics in Q2 2020 and held it in 2 quarters.
  • Bain Capital Life Sciences Investors's Sage Therapeutics position peaked at $30.5M in Q3 2020.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2020, filed 16 Feb 2021.